• Xenon Pharmaceuticals President and CEO Ian Mortimer bought 30,000 common shares at USD 37.38 each.
• Directly held stake rose to 49,923 common shares following the purchase.
• Additional 14,300 common shares were reported as indirectly held by his spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-409999), on October 01, 2026, and is solely responsible for the information contained therein.